IP Library Granted Patent US 8,329,465
Granted Patent B2
US 8,329,465 · App. 12/986,111 · Granted Dec 11, 2012

Recombinant cell clones having increased stability and methods of making and using the same

Assignee: Baxter Innovations GmbH
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,329,465
App. No.
12/986,111
Granted
Dec 11, 2012
Kind
B2
Abstract

Disclosed are a stable recombinant cell clones which are stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum- and protein-free culturing conditions, and a method of preparing recombinant proteins by means of the biomass. Furthermore, the invention relates to a method of recovering stable recombinant cell clones.

Claims (13)

1. A method for obtaining a stable recombinant mammalian cell clone that produces a recombinant product and is stable under production conditions in serum- and protein-free medium for at least 40 generations, the method comprising:

providing a recombinant original mammalian cell clone, wherein the recombinant original mammalian cell clone has a selection marker,

cultivating the recombinant original cell clone on serum-containing medium,

adapting the cells to serum- and protein-free medium with neither selection pressure for the selection marker nor selection for a polypeptide factor that replaces serum components,

testing the cell culture after adaptation for stable product-producers with neither selection pressure for the selection marker nor selection for a polypeptide factor that replaces serum components, and

cloning a stable product-producer-cell clone in serum- and protein-free conditions with neither selection pressure for the selection marker nor selection for a polypeptide factor that replaces serum components.

2. The method according to claim 1 , wherein the stable product-producer cell clone obtained is present in isolated form after the step of cloning.

3. The method according to claim 1 , wherein the recombinant cell clone comprises a nucleic acid encoding a recombinant polypeptide or protein.

4. The method according to claim 1 , wherein the recombinant product is Factor VIII.

5. The method according to claim 1 , wherein the recombinant product is Factor IX.

6. The method according to claim 1 , wherein the recombinant product is Factor VII.

7. The method according to claim 1 , wherein the recombinant product is von Willebrand factor (vWF).

8. The method according to claim 1 , wherein the original mammalian cell clone is a CHO cell clone.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2015
From: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE SA
To: BAXALTA INCORPORATED; BAXALTA GMBH
Reel/Frame 036825/0963 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 16, 2015
From: BAXTER INNOVATIONS GMBH
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE S.A.
Reel/Frame 035424/0172 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2011
From: REITER, MANFRED; MUNDT, WOLFGANG; DORNER, FRIEDRICH
To: BAXTER AKTIENGESELLSCHAFT
Reel/Frame 026902/0994 →
CHANGE OF NAME Recorded Mar 7, 2011
From: BAXTER AKTIENGESELLSCHAFT
To: BAXTER INNOVATIONS GMBH
Reel/Frame 025914/0023 →
Priority Claims (1)
AT 1073/97 · Jun 20, 1997 · national
Continuity (7)
Continuation 12488441 · Jun 19, 2009
Continuation 11482504 · Jul 7, 2006
Division 11123362 · May 6, 2005
Continuation 10170661 · Jun 12, 2002
Continuation 09324612 · Jun 2, 1999
Continuation In Part 09100253 · Jun 19, 1998
Related Publication 20110104758A1 · May 5, 2011